NASDAQ: LUCD
Lucid Diagnostics Inc Stock

$1.39+0.11 (+8.59%)
Updated Mar 14, 2025
LUCD Price
$1.39
Fair Value Price
$0.29
Market Cap
$82.49M
52 Week Low
$0.63
52 Week High
$1.63
P/E
-1.23x
P/B
13.01x
P/S
9.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.19M
Earnings
-$44.82M
Gross Margin
-53%
Operating Margin
-1,069.18%
Profit Margin
-1,248.8%
Debt to Equity
2.57
Operating Cash Flow
-$44M
Beta
0.84
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

LUCD Overview

Lucid Diagnostics Incorporated is developing products to diagnose and treat conditions of the esophagus, including conditions arising from chronic heartburn which may lead to esophageal cancer. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test, and EsoCheck, an esophageal cell collection device. Lucid Diagnostics was incorporated in 2018 and is headquartered in New York, NY.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LUCD's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
LUCD
Ranked
#102 of 106

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$9.61A
$24.62A
$17.25A
View Top Medical Device Stocks

Be the first to know about important LUCD news, forecast changes, insider trades & much more!

LUCD News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LUCD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LUCD ($1.39) is overvalued by 383.23% relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LUCD ($1.39) is not significantly undervalued (383.23%) relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LUCD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LUCD due diligence checks available for Premium users.

Valuation

LUCD fair value

Fair Value of LUCD stock based on Discounted Cash Flow (DCF)

Price
$1.39
Fair Value
$0.29
Overvalued by
383.23%
LUCD ($1.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LUCD ($1.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LUCD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LUCD price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.23x
Industry
41.08x
Market
3,446.57x

LUCD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
13.01x
Industry
3.94x
LUCD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LUCD's financial health

Profit margin

Revenue
$1.2M
Net Income
-$12.4M
Profit Margin
-1,055.5%
LUCD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LUCD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$22.6M
Liabilities
$16.3M
Debt to equity
2.57
LUCD's short-term assets ($16.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LUCD's short-term assets ($16.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LUCD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.2M
Investing
-$350.0k
Financing
$94.0k
LUCD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LUCD vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LUCDD$82.49M+8.59%-1.23x13.01x
MGRM$82.22M+0.87%-4.57x5.67x
NSPR$83.13M-2.44%-3.68x2.30x
ICCMC$77.79M+2.90%-4.98x7.73x
SRTSC$76.70M+4.97%11.34x1.37x

Lucid Diagnostics Stock FAQ

What is Lucid Diagnostics's quote symbol?

(NASDAQ: LUCD) Lucid Diagnostics trades on the NASDAQ under the ticker symbol LUCD. Lucid Diagnostics stock quotes can also be displayed as NASDAQ: LUCD.

If you're new to stock investing, here's how to buy Lucid Diagnostics stock.

What is the 52 week high and low for Lucid Diagnostics (NASDAQ: LUCD)?

(NASDAQ: LUCD) Lucid Diagnostics's 52-week high was $1.63, and its 52-week low was $0.63. It is currently -14.88% from its 52-week high and 120.63% from its 52-week low.

How much is Lucid Diagnostics stock worth today?

(NASDAQ: LUCD) Lucid Diagnostics currently has 59,342,479 outstanding shares. With Lucid Diagnostics stock trading at $1.39 per share, the total value of Lucid Diagnostics stock (market capitalization) is $82.49M.

Lucid Diagnostics stock was originally listed at a price of $11.76 in Oct 14, 2021. If you had invested in Lucid Diagnostics stock at $11.76, your return over the last 3 years would have been -88.18%, for an annualized return of -50.92% (not including any dividends or dividend reinvestments).

How much is Lucid Diagnostics's stock price per share?

(NASDAQ: LUCD) Lucid Diagnostics stock price per share is $1.39 today (as of Mar 14, 2025).

What is Lucid Diagnostics's Market Cap?

(NASDAQ: LUCD) Lucid Diagnostics's market cap is $82.49M, as of Mar 17, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lucid Diagnostics's market cap is calculated by multiplying LUCD's current stock price of $1.39 by LUCD's total outstanding shares of 59,342,479.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.